Nephros Inc Revenue Growth Rates (NEPH), Current and Historic Growth - CSIMarket
CSIMarket
 


Nephros Inc   (NASDAQ: NEPH)
 

NEPH's Revenue Growth by Quarter and Year

Nephros Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NEPH/growth
https://api.csimarket.com/api/v1/companies/NEPH/fundamentals
https://api.csimarket.com/api/v1/companies/NEPH/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
NEPH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.62
2nd Quarter June 6.02
1st Quarter March 4.99
FY 16.63

NEPHs Annual Revenue
Nephros Inc 's Revenue in the fiscal year 2025 $ 18.63 millions
Nephros Inc 's Revenue in the fiscal year 2024 $ 13.72 millions
Nephros Inc 's Revenue in the fiscal year 2023 $ 13.41 millions
Nephros Inc 's Revenue in the fiscal year 2022 $ 9.98 millions
Nephros Inc 's Revenue in the fiscal year 2021 $ 10.40 millions




NEPH Revenue third quarter 2026 Y/Y Growth Comment
Nephros Inc achieved in the third quarter 2026, above Company average Revenue rise of 43.42% year on year, to $ 5.62 millions.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 23 other companies have achieved higher Revenue growth. While Nephros Inc ' s Revenue jump of 43.42% ranks overall at the positon no. 408 in the third quarter 2026.




NEPH Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 43.42 %
2nd Quarter June 58.42 %
1st Quarter March 20.24 %
FY   -

Financial Statements
Nephros Inc 's third quarter 2026 Revenue $ 5.62 millions NEPH's Income Statement
Nephros Inc 's third quarter 2025 Revenue $ 3.92 millions Quarterly NEPH's Income Statement


NEPH Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -6.61 %
2nd Quarter June 20.64 %
1st Quarter March -26.18 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #106
Overall #408

Revenue Y/Y Growth Statistics
High Average Low
96.09 % 22.14 % -52.59 %
(Jun 30 2015)   (Mar 31 2021)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #106
Overall #408
Revenue Y/Y Growth Statistics
High Average Low
96.09 % 22.14 % -52.59 %
(Jun 30 2015)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nephros Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
100 % 7.06 % -43.56 %
(Sep 30 2012)  


NEPH's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Nephros Inc disclosed decline in Revenue from the second quarter by -6.61% to $ 5.62 millions, from $ 6.02 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 23 other companies have achieved higher Revenue quarter on quarter growth. While Nephros Inc 's Revenue growth quarter on quarter, overall rank is 505.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #99
Overall #505
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #24
Healthcare Sector #99
Overall #505
Revenue Q/Q Growth Statistics
High Average Low
100 % 7.06 % -43.56 %
(Sep 30 2012)  


NEPH's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Nephros Inc disclosed decline in Revenue from the second quarter by -6.61% to $ 5.62 millions, from $ 6.02 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 23 other companies have achieved higher Revenue quarter on quarter growth. While Nephros Inc 's Revenue growth quarter on quarter, overall rank is 505.


Nephros Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 21.69
Y / Y Revenue Growth (TTM) 39.25 %
Year on Year Revenue Growth Overall Ranking # 747
Seqeuential Revenue Change (TTM) 11.42 %
Seq. Revenue Growth (TTM) Overall Ranking # 1959


Cumulative Revenue growth Comment
Nephros Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 39.25% year on year, to $ 22 millions if the fiscal year would have ended in Jun 30 2026.
Nephros Inc 's trailing twelve months Revenue growth was higher than company's average 38.21% and higher than 32.5% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 11.42 % from $19.46 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at27.46%.

In the Healthcare sector 155 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 747, from total ranking in previous quarter at 1075.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 111
Healthcare Sector # 156
Overall # 747

Revenue TTM Y/Y Growth Statistics
High Average Low
251.72 %
38.21 %
-20.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 111
Sector # 302
S&P 500 # 1959
Cumulative Revenue growth Comment
Nephros Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 39.25% year on year, to $ 22 millions if the fiscal year would have ended in Jun 30 2026.
Nephros Inc 's trailing twelve months Revenue growth was higher than company's average 38.21% and higher than 32.5% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 11.42 % from $19.46 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at27.46%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 11.42 % increase from $19.46 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 155 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 747, from total ranking in previous quarter at 1075.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 111
Healthcare Sector # 156
Overall # 747

Revenue TTM Y/Y Growth Statistics
High Average Low
251.72 %
38.21 %
-20.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 111
Sector # 302
S&P 500 # 1959




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NEPH's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions


About Nephros Inc Revenue Growth Rates (NEPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nephros Inc (CIK 1196298).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-050218
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nephros Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.